Eli Lilly's weight-loss drug, Zepbound, is displayed in New York City on December 11, 2023.
Brendan McDiarmid | Reuters
All doses Eli Lilly Popular weight-loss shot Zepbound and diabetes drug Mounjaro are now available in the United States, according to an update to the U.S. Food and Drug Administration's drug shortage database on Friday.
A previous update said some doses of the treatments were still in short supply. Some doses of Mojaro have been in short supply since early 2022, while doses of Zebound were added to the FDA’s shortage list earlier this year after its US approval in November.
Demand for weight-loss and diabetes drugs has outstripped supply for months, prompting Eli Lilly and its rival Novo Nordisk Investing billions of dollars to ramp up manufacturing.
The FDA update comes a day after Eli Lilly CEO David Ricks told Bloomberg that the shortage of Mounjaro and Zippond would end “very soon.”
“I think we are already planning today or tomorrow to exit this process,” he said in an interview with the agency.
An Eli Lilly spokesperson did not immediately respond to CNBC's request for comment on the FDA's update on Friday.
According to the U.S. Food and Drug Administration's database, all doses of Novo Nordisk's diabetes shot Ozempic were available in the United States as of Friday. Meanwhile, the FDA said some doses of Novo Nordisk's weight-loss drug Wegovy are in limited supply.
